



Advances in Cancer Epigenetics

Guest Editors:

Prof. Dr. Noël J. Raynal

Département de Pharmacologie
et de Physiologie, Université de
Montréal and Sainte-Justine
University Hospital Research
Center, Montréal, QC, Canada

Prof. Dr. Serge McGraw

1. Department of Biochemistry
and Molecular Medicine,
Université de Montréal, Montreal,
QC, Canada
2. Centre de recherche du CHU
Sainte-Justine, Montreal, QC,
Canada
3. Department of Obstetrics and
Gynecology, Université de
Montréal, Montreal, QC, Canada

Deadline for manuscript
submissions:

closed (15 June 2023)

Message from the Guest Editors

Dear Colleagues,

The alteration of the epigenome profiles is a hallmark of virtually all cancers. New advances in cancer epigenetics highlight the complexity and intricacy of various epigenetic modifications from early steps of neoplasia, cancer stem cell maintenance, and metastasis. The importance of metabolism alterations and toxicant exposure play a clear role in carcinogenesis and response to therapy. The understating of the coordination between active and repressive epigenetic marks has increased considerably in recent years and leads to tailored epigenetic therapeutics, which represent the future of precision medicine.

Prof. Dr. Noël J. Raynal

Prof. Dr. Serge McGraw

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)